Sotatercept (sotatercept-csrk) price revealed and formal purchasing channels

Sotatercept(sotatercept-csrk) is an innovative drug specially used to treatpulmonary arterial hypertension (PAH). PAH is a rare and severe progressive cardiovascular disease in which the patient's pulmonary artery pressure and resistance are abnormally elevated, leading to right ventricular hypertrophy and dysfunction, which may even be life-threatening in severe cases. The launch of Sotercept provides new treatment options for PAH patients.

Sotecept, developed by Merck & Co. of the United States, is the world's first activin signaling inhibitor therapy for the treatment ofPAH. It improves the balance between pro-proliferation and anti-proliferation signals by selectively binding to ligands of transforming growth factor-β (TGF-β) superfamily members, thereby regulating the proliferation of pulmonary arteries, reversing the excessive proliferation and remodeling of pulmonary arterioles, and thereby reducing pulmonary artery pressure. This unique mechanism of action gives Sotercept significant advantages in the treatment of PAH.

Clinical trial results show that Sotecept can significantly improvePAH patients’ exercise capacity and improve their quality of life. At the same time, the drug can also reduce the patient's pulmonary vascular resistance, further proving its effectiveness in improving the condition of PAH patients. In addition, sotercept also has good safety and tolerability, providing patients with a more reliable treatment option.

Currently, Sotercept has received regulatory approval for marketing in many countries and regions, including the United States and the European Union. Since Sotercept is not currently on the market in China, domestic patients cannot directly purchase this drug for the time being. However, according to reliable information, Sotexip has been sold overseas, and the price is about 69,000 yuan per box. If the patient needs this drug, please consult a regular overseas medical consultant for information.

Reference materials:https://www.drugs.com/monograph/sotatercept-csrk.html